CA3241298A1 - Antagonists of the muscarinic acetylcholine receptor m4 - Google Patents
Antagonists of the muscarinic acetylcholine receptor m4Info
- Publication number
- CA3241298A1 CA3241298A1 CA3241298A CA3241298A CA3241298A1 CA 3241298 A1 CA3241298 A1 CA 3241298A1 CA 3241298 A CA3241298 A CA 3241298A CA 3241298 A CA3241298 A CA 3241298A CA 3241298 A1 CA3241298 A1 CA 3241298A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- mmol
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163284750P | 2021-12-01 | 2021-12-01 | |
| US63/284,750 | 2021-12-01 | ||
| PCT/US2022/051493 WO2023102100A1 (en) | 2021-12-01 | 2022-12-01 | Antagonists of the muscarinic acetylcholine receptor m4 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3241298A1 true CA3241298A1 (en) | 2023-06-08 |
Family
ID=84943708
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3241298A Pending CA3241298A1 (en) | 2021-12-01 | 2022-12-01 | Antagonists of the muscarinic acetylcholine receptor m4 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250145595A1 (https=) |
| EP (1) | EP4441046A1 (https=) |
| JP (1) | JP2024543973A (https=) |
| KR (1) | KR20240112343A (https=) |
| CN (2) | CN116669737A (https=) |
| AU (1) | AU2022400780A1 (https=) |
| CA (1) | CA3241298A1 (https=) |
| IL (1) | IL313219A (https=) |
| MX (1) | MX2024006718A (https=) |
| WO (1) | WO2023102100A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018300980A1 (en) | 2017-07-12 | 2020-01-02 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| IL273924B2 (en) | 2017-10-20 | 2024-07-01 | Univ Vanderbilt | Antagonists of the muscarinic acetylcholine receptor m4 |
| CA3155864A1 (en) | 2019-10-04 | 2021-04-08 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| EP4491228A3 (en) * | 2020-12-22 | 2025-04-23 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112018003417B1 (pt) * | 2016-06-22 | 2023-10-24 | Vanderbilt University | Composto modulador alostérico positivo do receptor muscarínico de acetilcolina m4 e composição farmacêutica que o compreende |
| JP2020530451A (ja) * | 2017-08-08 | 2020-10-22 | ヴァンダービルト ユニバーシティー | ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト |
| IL273924B2 (en) * | 2017-10-20 | 2024-07-01 | Univ Vanderbilt | Antagonists of the muscarinic acetylcholine receptor m4 |
| WO2021119254A1 (en) * | 2019-12-10 | 2021-06-17 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| US20230183218A1 (en) * | 2020-04-24 | 2023-06-15 | Vanderbilt University | Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4 |
| EP4139303A1 (en) * | 2020-04-24 | 2023-03-01 | Vanderbilt University | Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4 |
-
2021
- 2021-12-22 CN CN202180087480.8A patent/CN116669737A/zh active Pending
-
2022
- 2022-12-01 AU AU2022400780A patent/AU2022400780A1/en active Pending
- 2022-12-01 EP EP22843543.4A patent/EP4441046A1/en active Pending
- 2022-12-01 CA CA3241298A patent/CA3241298A1/en active Pending
- 2022-12-01 JP JP2024532491A patent/JP2024543973A/ja active Pending
- 2022-12-01 KR KR1020247021498A patent/KR20240112343A/ko active Pending
- 2022-12-01 IL IL313219A patent/IL313219A/en unknown
- 2022-12-01 US US18/715,048 patent/US20250145595A1/en active Pending
- 2022-12-01 MX MX2024006718A patent/MX2024006718A/es unknown
- 2022-12-01 WO PCT/US2022/051493 patent/WO2023102100A1/en not_active Ceased
- 2022-12-01 CN CN202280088712.6A patent/CN118541365A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022400780A1 (en) | 2024-06-20 |
| CN118541365A (zh) | 2024-08-23 |
| MX2024006718A (es) | 2024-08-09 |
| JP2024543973A (ja) | 2024-11-26 |
| EP4441046A1 (en) | 2024-10-09 |
| KR20240112343A (ko) | 2024-07-18 |
| IL313219A (en) | 2024-07-01 |
| US20250145595A1 (en) | 2025-05-08 |
| CN116669737A (zh) | 2023-08-29 |
| WO2023102100A1 (en) | 2023-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4037677B1 (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| EP4267569B1 (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| US20250145595A1 (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| EP4072679A1 (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| WO2022216655A1 (en) | N-(6-((octahydrocyclopenta[c]pyrrol-5-yi)amino)pyridazin-3-yl)phenyl)carboxamide and (6- ((octahydrocyclopenta[c]pyrrol-5-yl)amino)pyridazin-3-yl)benzamide derivatives as machr m4 antagonists for the treatment of neurodegenerative disorders | |
| CA3180717A1 (en) | Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4 | |
| US20230150986A1 (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| US20240174655A1 (en) | Indazole derivatives as antagonists of the muscarinic acetylcholine receptor m4 | |
| EP4247803A1 (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| WO2022261427A1 (en) | (4-(6-((2-octahydrocyclopenta[c]pyrrol-5-yl)amino)pyridazin-3-yl)phenyl)(imino)(methyl)-lambda6- sulfanone derivatives and similar compounds as muscarinic acetylcholine receptor m4 antagonists for the treatment of neurodegenerative disorders | |
| EP4196473B1 (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| HK40121280A (en) | Antagonists of the muscarinic acetylcholine receptor m4 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W00-W00-W160 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: INACTIVE: COVER PAGE PUBLISHED Effective date: 20240702 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241122 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250203 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250203 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251007 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251007 |